Dahiroc, Rachel L.
HRN: 04-03-01 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/09/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/09/2025
06/16/2025
IV
250mg
Q24H
UTI
Waiting Final Action
Indication: Culture-directed Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: No Wrong Dose 427.5 MG Q48 HOURS (PNF)
Final appropriateness: Yes
Overall appropriateness: Yes